BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1794 related articles for article (PubMed ID: 19219026)

  • 1. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.
    Gao P; Tchernyshyov I; Chang TC; Lee YS; Kita K; Ochi T; Zeller KI; De Marzo AM; Van Eyk JE; Mendell JT; Dang CV
    Nature; 2009 Apr; 458(7239):762-5. PubMed ID: 19219026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.
    Liu W; Le A; Hancock C; Lane AN; Dang CV; Fan TW; Phang JM
    Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8983-8. PubMed ID: 22615405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC, microRNAs and glutamine addiction in cancers.
    Dang CV
    Cell Cycle; 2009 Oct; 8(20):3243-5. PubMed ID: 19806017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
    Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
    Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.
    Dang CV
    Cancer Res; 2010 Feb; 70(3):859-62. PubMed ID: 20086171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.
    Wise DR; DeBerardinis RJ; Mancuso A; Sayed N; Zhang XY; Pfeiffer HK; Nissim I; Daikhin E; Yudkoff M; McMahon SB; Thompson CB
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18782-7. PubMed ID: 19033189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
    Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
    Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC-induced cancer cell energy metabolism and therapeutic opportunities.
    Dang CV; Le A; Gao P
    Clin Cancer Res; 2009 Nov; 15(21):6479-83. PubMed ID: 19861459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
    Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
    Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NF-κB member p65 controls glutamine metabolism through miR-23a.
    Rathore MG; Saumet A; Rossi JF; de Bettignies C; Tempé D; Lecellier CH; Villalba M
    Int J Biochem Cell Biol; 2012 Sep; 44(9):1448-56. PubMed ID: 22634383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
    Li J; Li X; Wu L; Pei M; Li H; Jiang Y
    Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the oxidative stress-induced miR-23a protects the human retinal pigment epithelium (RPE) cells from apoptosis through the upregulation of glutaminase and glutamine uptake.
    Li DD; Zhong BW; Zhang HX; Zhou HY; Luo J; Liu Y; Xu GC; Luan CS; Fang J
    Mol Biol Rep; 2016 Oct; 43(10):1079-87. PubMed ID: 27411920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?
    Dang CV
    Cell Cycle; 2010 Oct; 9(19):3884-6. PubMed ID: 20948290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer.
    Qu X; Sun J; Zhang Y; Li J; Hu J; Li K; Gao L; Shen L
    Biochem Biophys Res Commun; 2018 Oct; 504(2):415-421. PubMed ID: 30103944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutaminases regulate glutathione and oxidative stress in cancer.
    Matés JM; Campos-Sandoval JA; de Los Santos-Jiménez J; Márquez J
    Arch Toxicol; 2020 Aug; 94(8):2603-2623. PubMed ID: 32681190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach.
    Chen L; Cui H
    Int J Mol Sci; 2015 Sep; 16(9):22830-55. PubMed ID: 26402672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.
    Jeong SM; Lee A; Lee J; Haigis MC
    J Biol Chem; 2014 Feb; 289(7):4135-44. PubMed ID: 24368766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactate promotes glutamine uptake and metabolism in oxidative cancer cells.
    Pérez-Escuredo J; Dadhich RK; Dhup S; Cacace A; Van Hée VF; De Saedeleer CJ; Sboarina M; Rodriguez F; Fontenille MJ; Brisson L; Porporato PE; Sonveaux P
    Cell Cycle; 2016; 15(1):72-83. PubMed ID: 26636483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myc requires RhoA/SRF to reprogram glutamine metabolism.
    Haikala HM; Marques E; Turunen M; Klefström J
    Small GTPases; 2018 May; 9(3):274-282. PubMed ID: 27532209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 90.